• Chin Hock Goh, Hin Hock Goh, Wei Qi Leong, Min Hoe Chew, Yihui Summer Pan, Lim Kiat Hon Tony, Lita Chew, Iain Bee Huat Tan, Han Chong Toh, Choong Leong Tang, Wan Pei Cherylin Fu, and Whay Kuang Chia.
• Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
• Anticancer Res. 2014 Dec 1; 34 (12): 7407-14.

BackgroundRecent observational studies suggest that postoperative aspirin use may improve Colorectal cancer (CRC)-specific survival and overall survival (OS). In this study, we aimed to assess the effects of aspirin use on outcomes in a predominantly Asian cohort of patients with CRC.Patients And MethodsCase records of patients undergoing curative resection for stage I-III CRC were retrieved for clinical data and patterns of aspirin use and vital data were determined from hospital electronic prescription records, hospital pharmacy dispensing records, national clinical and prescription databases. CRC-specific and recurrence-free survival (RFS) amongst aspirin users and non-users were analyzed and compared using the Cox proportional hazards model.ResultsOut of 726 patients with CRC, 103 were regular aspirin users and 623 were non-users. The median age of the cohort was 65 years (range=22-94 years) and the majority of patients were Chinese (90%). Nineteen percent, 31% and 47% had stage I, II and III CRC respectively; tumor staging was unknown for 3%. After adjusting for prognostic factors (age, stage, lymph node stage, grade, lesion site, perineural invasion, lymphvascular invasion), the risk of CRC relapse or death from CRC was approximately 60% lower compared to patients who were not postoperative aspirin users (Hazard Ratio=0.38, 95% Confidence Interval=0.17-0.84, p=0.017). No benefit was observed for preoperative use of aspirin.ConclusionIn this single-Institution study, with long-term follow-up of patients with stage I-III-resected CRC, postoperative aspirin use was associated with reduced risk of relapse of and death from CRC.Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

23 keywords...

hide…